JAK1 and neoplasm: In the MC38 model, the significant antitumor activity of anti-PD-1 against the parental was lost in JAK1/2 and B2M KOs (Table1); in these KO sublines, CyTOF analysis revealed that anti-PD-1 therapy was unable to change tumor CD8 T-cell infiltration.